DTC Act of 2025
- Bill Number
- H.R. 3789
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-06-05: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2026-01-14T09:06:55Z
AI-Generated Summary
Purpose of the Legislation
The Drug-price Transparency for Consumers Act of 2025 (H.R. 3789) aims to increase transparency in prescription drug and biological product pricing by requiring direct-to-consumer (DTC) advertisements to disclose key cost information. This is intended to help consumers make informed decisions, promote market competition, and potentially reduce wasteful spending in federal programs like Medicare and Medicaid.
Key Provisions
- Mandatory Disclosure in DTC Ads: Starting July 1, 2026, DTC advertisements for prescription drugs or biological products covered under Medicare (Title XVIII) or Medicaid (Title XIX) must include a clear and conspicuous disclosure of the wholesale acquisition cost (WAC)—a standard list price set by the manufacturer—for a 30-day supply or a typical course of treatment (as defined on the product's approved label).
- Exemption for Low-Cost Products: The requirement does not apply to drugs or biologicals with a WAC under $35 for the specified supply or course.
- Additional Guidance in Disclosures: Ads may note that a consumer's actual out-of-pocket cost could differ based on their health insurance coverage.
- Rulemaking by the Secretary of Health and Human Services (HHS): Within one year of enactment, HHS must issue final regulations specifying how the WAC disclosure should appear in visual and audio formats across different media (e.g., TV, print, online) and how quickly manufacturers must update ads if prices change.
- Enforcement and Penalties: Violations can result in civil money penalties of up to $100,000 per instance, enforced similarly to other healthcare penalties under the Social Security Act. HHS may use public reporting to monitor compliance.
- Definitions:
- Prescription drug: FDA-approved drugs requiring a prescription.
- Biological product: FDA-licensed biologics (complex medicines derived from living organisms) requiring a prescription.
- Wholesale acquisition cost (WAC): The manufacturer's published list price before discounts or rebates.
- Funding: Authorizes necessary appropriations to implement the law.
The bill amends Part A of Title XI of the Social Security Act by adding a new section (1150D).
Significant Changes to Existing Law
- Builds on current FDA regulations for DTC ads, which already mandate disclosures about side effects, risks (contraindications), and effectiveness, by adding a pricing disclosure requirement.
- Introduces the first federal mandate for price transparency specifically in DTC ads, addressing a gap where ads promote drugs without cost information, unlike other consumer products.
- Applies only to drugs/biologics payable under Medicare or Medicaid and featured in ads subject to FDA oversight, narrowing the scope from all DTC ads.
Potential Impacts
- On Citizens: Consumers, especially those with high-deductible health plans or coinsurance (where they pay a percentage of costs), may better estimate and afford medications, potentially leading to fewer unfilled prescriptions (e.g., studies cited show 25% of cancer patients skip meds due to cost). This could encourage price shopping and selection of lower-cost alternatives.
- On Government Agencies: HHS, FDA, and Centers for Medicare & Medicaid Services (CMS) will need resources for rulemaking, enforcement, and monitoring, but could see slowed growth in federal drug spending (e.g., ads drove 58% of Medicare drug costs from 2016-2018). No direct international impacts are outlined, though it aligns with U.S.-unique DTC ad practices (only allowed in the U.S. and New Zealand).
- Broader Effects: May reduce demand for high-cost, newly approved drugs promoted via ads, fostering competition and efficiency in the pharmaceutical market.
Main Stakeholders Affected
- Pharmaceutical Manufacturers: Must revise ads, update pricing in real-time, and face penalties for non-compliance; this could alter marketing strategies and reduce ad-driven sales of expensive drugs.
- Consumers and Patients: Gain access to objective price info before doctor visits, empowering informed choices, particularly for the half of Americans in high-deductible plans or Medicare beneficiaries using coinsurance.
- Healthcare Providers: Doctors may face fewer patient requests for advertised, high-cost drugs that aren't clinically optimal or have cheaper generic options.
- Government and Payers: HHS/FDA/CMS enforce the law; Medicare/Medicaid could benefit from lower spending on advertised drugs (e.g., $34 billion in 2018 for top 20 TV-advertised drugs).
- Insurers and Pharmacies: Indirectly affected as transparency may shift demand toward cost-effective options, potentially lowering overall system costs.
Notable Legal, Constitutional, or Political Implications
- Legal: Relies on HHS's existing authority over DTC ads (e.g., FDA rules on side effects) but introduces enforceable penalties tied to the Social Security Act, which could lead to litigation over compliance details like "clear and conspicuous" disclosures.
- Constitutional: May face First Amendment challenges as a restriction on commercial speech in ads, though it advances government interests in consumer protection and health spending efficiency (similar to upheld ad regulations). The bill's findings emphasize factual, non-controversial WAC disclosure to support informed decisions.
- Political: Reflects bipartisan concerns over drug pricing (introduced by Rep. Taylor and Rep. Schakowsky), aligning with prior laws like the 2021 Consolidated Appropriations Act's push for real-time benefit tools. It could influence ongoing debates on pharmaceutical competition and affordability without directly regulating prices.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Taylor, David J. [R-OH-2]
Cosponsors (8)
Rep. Schakowsky, Janice D. [D-IL-9], Rep. Begich, Nicholas J. [R-AK-At Large], Rep. Quigley, Mike [D-IL-5], Rep. Bresnahan, Robert P. [R-PA-8], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Nunn, Zachary [R-IA-3], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Hinson, Ashley [R-IA-2]
Recent Actions
- 2025-06-05: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-05: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-06-05: Introduced in House
- 2025-06-05: Introduced in House
Bill Versions
- Drug-price Transparency for Consumers Act of 2025 — issued 2025-06-05 — PDF (11 pages)